Multivalent Pneumococcal Vaccine Complexes for Durable T-Cell Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines for Streptococcus pneumoniae, such as PCV13 and PPSV23, fail to provide long-lasting T-cell dependent immunity against a broad range of serotypes, and existing multivalent vaccines do not induce sufficient immunogenicity to protect against invasive pneumococcal disease and pneumonia.

Innovation Solution

A multivalent pneumococcal vaccine composition comprising non-covalently associated biotinylated polysaccharide antigens and fusion proteins, including SPP2 and CPS, which synergistically enhance immune response and protection against invasive pneumococcal disease by inducing T- and B-cell responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PCV13 or PPSV23 vaccines are used, then protection against some serotypes is achieved, but long-lasting T-cell dependent immunity against a broad range of serotypes is not provided

Engineering Contradiction:

Improveprotection against pneumococcal diseaseVSAvoidduration of immunity

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The vaccine combines multiple components including protein conjugates with polysaccharides, T-cell epitopes, and adjuvants to create a composite immunogenic composition that elicits both B-cell and T-cell responses, providing long-lasting immunity against multiple serotypes

Inventive Principle:

Principle #40Composite materials

2Adaptability or versatility

If PPSV23 includes polysaccharide components of more serotypes, then broader serotype coverage is achieved, but the immune response is neither long-lasting nor anamnestic

Engineering Contradiction:

Improveserotype coverageVSAvoidduration of immune response

Core Design Contradiction:

Adaptability or versatilityVSDuration of action of moving object

Solution Approach 1:

The vaccine modifies the chemical and structural parameters of polysaccharide antigens by conjugating them to protein carriers and incorporating T-cell epitopes, transforming them from T-independent antigens to T-dependent antigens that elicit long-lasting and anamnestic immune responses

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If existing multivalent vaccines are used, then multiple serotypes are targeted, but sufficient immunogenicity to protect against invasive pneumococcal disease is not induced

Engineering Contradiction:

Improvenumber of serotypes targetedVSAvoidprotection efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The vaccine uses protein carriers and T-cell epitopes as intermediaries to bridge the interaction between polysaccharide antigens and the immune system, enabling T-cell dependent activation that enhances immunogenicity and protection efficacy across multiple serotypes

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The vaccine composition significantly increases protection against invasive pneumococcal disease by up to 10-fold compared to references, demonstrating enhanced immunogenicity and efficacy against a broad range of serotypes.

Implementation Method 1

non-covalently associated biotinylated polysaccharide antigens and fusion proteins

Methodology Applied

Scientific EffectNon-covalent association:

Implementation Method 2

high affinity (dissociation constant [KD]≈10-15M), non-covalent binding between biotin and rhizavidin

Methodology Applied

Scientific EffectBiotin binding:

Data Source

PatentUS12377140B2Multivalent pneumococcal vaccines

Publication Date: 2025.08.05 AFFINIVAX INC

AI summary

Technologies for the prevention and/or treatment of pneumococcal infections.